Drug Trial Radar · NCT02817841
E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study
Last checked: Nov 19, 2026Latest source record: Feb 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,148
Actual
Start
Aug 30, 2016
Primary completion
Oct 16, 2018
Study completion Nov 16, 2018
Sponsor
- Lead sponsor
- EstetraIndustry
- Sponsor type
- Industry
- Collaborators
- PRA Health Sciences
- First posted
- Jun 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 16 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 16 to 50 years.
Conditions
- Contraception
Interventions
15 mg E4/3 mg DRSPDrug
15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of On-treatment Pregnancies (With + 7-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 16 to 35 Years, Inclusive, at the Time of ScreeningTime frame: Up to 12 months (13 cycles with 1 cycle = 28 days)
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Thomas Jefferson University Obstetrics and Gynecology
Philadelphia, Pennsylvania
Clinique de Santé des Femmes
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.